Description

FLAGYL 200 MG SUSPENSION

Indications

FLAGYL 200 MG SUSPENSION is primarily indicated for the treatment of various infections caused by anaerobic bacteria and certain protozoa. It is commonly prescribed for conditions such as bacterial vaginosis, trichomoniasis, and infections of the gastrointestinal tract including amebiasis. Additionally, it is effective in treating infections caused by Clostridium difficile, a bacterium responsible for severe colitis. The suspension form is particularly useful for pediatric patients and individuals who may have difficulty swallowing tablets.

Mechanism of Action

The active ingredient in FLAGYL is metronidazole, which is an antiprotozoal and antibacterial agent. Metronidazole works by diffusing into the microbial cells and interfering with their DNA synthesis. It is selectively toxic to anaerobic organisms and protozoa, leading to cell death. The drug is reduced by ferredoxin, a protein found in anaerobic bacteria, resulting in the formation of reactive intermediates that damage DNA and inhibit nucleic acid synthesis. This mechanism makes FLAGYL effective against a range of infections caused by susceptible organisms.

Pharmacological Properties

FLAGYL is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 3 hours after administration. The bioavailability of metronidazole is approximately 80% when taken orally. The drug is widely distributed throughout the body, including the central nervous system, and is metabolized primarily in the liver. The elimination half-life of metronidazole ranges from 8 to 10 hours, with metabolites excreted mainly through the urine. FLAGYL is effective against both aerobic and anaerobic bacteria, making it a versatile treatment option.

Contraindications

FLAGYL 200 MG SUSPENSION is contraindicated in patients with a known hypersensitivity to metronidazole or any of its components. Caution should be exercised in individuals with a history of blood dyscrasias, liver disease, or neurological disorders. The use of FLAGYL during the first trimester of pregnancy is generally avoided unless the potential benefits outweigh the risks, as it may pose a risk to the developing fetus. Additionally, it should not be used in patients who are currently consuming alcohol or have consumed alcohol within the last 48 hours due to the risk of a disulfiram-like reaction.

Side Effects

Common side effects associated with FLAGYL 200 MG SUSPENSION include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Other potential side effects may include headache, dizziness, and a metallic taste in the mouth. Rare but serious side effects can occur, including peripheral neuropathy, seizures, and hypersensitivity reactions such as rash or urticaria. Patients should be advised to report any unusual symptoms or severe side effects to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of FLAGYL 200 MG SUSPENSION varies based on the specific infection being treated and the age of the patient. For adults, the typical dosage for bacterial vaginosis is 500 mg orally twice daily for 7 days. For trichomoniasis, a single dose of 2 grams is often prescribed. In pediatric patients, the dosage is typically based on body weight, with a common recommendation of 15 mg/kg/day divided into two or three doses. It is important to follow the prescribing physician’s instructions and complete the entire course of treatment, even if symptoms improve before the medication is finished.

Interactions

FLAGYL may interact with several medications, potentially altering their effects. Notably, concurrent use of alcohol should be avoided, as it can lead to a disulfiram-like reaction characterized by flushing, nausea, vomiting, and palpitations. Additionally, metronidazole may enhance the anticoagulant effect of warfarin, necessitating close monitoring of INR levels. Other medications that may interact with FLAGYL include lithium, phenytoin, and certain antiepileptic drugs. Patients should inform their healthcare provider of all medications they are currently taking to prevent potential interactions.

Precautions

Prior to initiating treatment with FLAGYL 200 MG SUSPENSION, healthcare providers should assess the patient’s medical history, particularly regarding liver function and any history of neurological disorders. Caution is advised in patients with a history of blood dyscrasias, as metronidazole may cause bone marrow suppression. It is also important to monitor for signs of peripheral neuropathy during prolonged therapy. Pregnant and breastfeeding women should discuss the risks and benefits of using FLAGYL with their healthcare provider to ensure the safety of both mother and child.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of FLAGYL in treating various infections. For instance, a randomized controlled trial published in the Journal of Antimicrobial Chemotherapy found that metronidazole was significantly more effective than placebo in treating bacterial vaginosis, with a cure rate exceeding 80%. Another study in the New England Journal of Medicine highlighted the effectiveness of metronidazole in the treatment of Clostridium difficile-associated diarrhea, showing a marked reduction in recurrence rates when compared to other treatments. These studies underscore the importance of FLAGYL as a first-line treatment option for specific infections.

Conclusion

FLAGYL 200 MG SUSPENSION is a vital therapeutic agent in the management of various anaerobic bacterial and protozoal infections. Its unique mechanism of action, pharmacological properties, and established efficacy make it a preferred choice among healthcare providers. While generally well-tolerated, awareness of potential side effects, contraindications, and drug interactions is essential for ensuring patient safety. As with any medication, it is crucial for patients to adhere to the prescribed regimen and consult their healthcare provider with any concerns regarding their treatment.